SEC Form 4 · accession 0001123292-17-001399
Innovation Pharmaceuticals Inc. · IPIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jane A. Harness
Officer — Vice President
Period of report
Sep 1, 2017
Accepted (ET)
Sep 6, 2017 · 6:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001355250
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF1 | Sep 1, 2017 | A | 58,394 | $0.00 | A | 116,788 | D | |
| Class A Common StockF2 | Sep 1, 2017 | F | 6,056 | $0.71 | D | 110,732 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F3 | $0.71 | Sep 1, 2017 | A | 172,987 | A | — | Sep 1, 2027 | Class A Common Stock | 172,987 | 172,987 | D |
Explanation of responses
- F1Represents restricted stock vesting in three equal annual installments beginning on September 1, 2018.
- F2Represents shares withheld for payment of tax liability arising as a result of the partial settlement of restriced stock awards that vested.
- F3The option vests in three equal annual installments on September 1, 2018, 2019 and 2020.